{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["73(9)"],"submitter":["Messina C"],"funding":["Università degli Studi di Firenze"],"pubmed_abstract":["<h4>Background</h4>Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aims to investigate clinical and pathological characteristics of mRCC patients who achieved long-term responses during nivolumab treatment.<h4>Materials and methods</h4>A retrospective analysis was performed on mRCC patients receiving nivolumab as second or further therapy line between May 2016 and January 2019 in 34 Italian Oncology Centres. Outcome assessments and logistic regression were performed to evaluate factors influencing long-term responses.<h4>Results</h4>A total of 571 patients with a median age of 61 years (range 17-85) were included in"],"journal":["Cancer immunology, immunotherapy : CII"],"pagination":["161"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11219688"],"repository":["biostudies-literature"],"pubmed_title":["Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study."],"pmcid":["PMC11219688"],"pubmed_authors":["Maruzzo M","Sbrana A","Zucal PA","Catalano F","Morelli F","Masini C","Rebuzzi SE","Roviello G","Naglieri E","Pedrazzoli P","Catalano M","Gandini A","Pipitone S","Panni S","De Giorgi U","Prati G","Banna GL","Buti S","Messina M","Mollica V","Ricotta R","Prati V","Atzori F","Di Napoli M","Nole F","Fornarini G","Rescigno P","Fratino L","Soraru M","Vignani F","Tudini M","Messina C","Milella M","Procopio G","Signori A","Cavo A","Malgeri A"],"additional_accession":[]},"is_claimable":false,"name":"Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.","description":"<h4>Background</h4>Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aims to investigate clinical and pathological characteristics of mRCC patients who achieved long-term responses during nivolumab treatment.<h4>Materials and methods</h4>A retrospective analysis was performed on mRCC patients receiving nivolumab as second or further therapy line between May 2016 and January 2019 in 34 Italian Oncology Centres. Outcome assessments and logistic regression were performed to evaluate factors influencing long-term responses.<h4>Results</h4>A total of 571 patients with a median age of 61 years (range 17-85) were included in","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T19:23:15.003Z","creation":"2025-04-04T19:23:15.003Z"},"accession":"S-EPMC11219688","cross_references":{"pubmed":["38954006"],"doi":["10.1007/s00262-024-03741-2"]}}